A new molecule developed by University at Buffalo researchers acts like a local, long-lasting anesthetic, providing robust ...

Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

Ben Hargreaves finds that a new line of attack could be the development of more effective non-opioid painkillers, with one potential therapy moving closer to approval. The opioid epidemic in the ...

Final enrollment concludes for Spark Biomedical's pivotal study investigating a non-invasive, drug-free neurostimulation ...

DelveInsight's Cancer Pain Market Insights report includes a comprehensive understanding of current treatment practices, ...

Already, the Food and Drug Administration has approved four ... What’s more, the effects of mAbs last longer than opioids and non-steroidal anti-inflammatory drugs (NSAIDs).

The hope is that a new generation of non-opioid analgesics will become available to treat both acute and chronic pain and have a reduced risk of addiction. In 2023, more than 100,000 lives were ...

Vascarta Inc., a biopharmaceutical company committed to advancing innovative therapies for underserved patient populations, ...

Assemblyman Robert Smullen, R,C-Mohawk Valley and the Adirondacks. held a press conference alongside Co-Founder of the ...

Fatal overdoses among US youth from synthetic opioids alone surged from 2018 to 2022, surpassing deaths from polydrug ...

A host of big-name investors from Tom Hardy to Bill Moss are backing a health company aiming to take curcumin mainstream.